PsyIndex Weekly Update

August 2, 2021 – August 6, 2021
The PsyIndex extended its move lower over the past week, even as two companies moved to senior stock exchanges. Investors will continue to keep an eye on several ongoing clinical trials, as well as private companies that are gearing up to go public over the coming quarters.

Market Performance

Weekly Performance: $128.84 (-2.22%)

Powered by

CFN Enterprises Inc. (OTCQB: CNFN)

Top Gainers

Top Decliners

View All Index Constituents

Corporate News, Deals & Listings

  • KetamineOne Capital Ltd. (NEO: MEDI) (OTC: KONEF) signed an exclusive agreement for the use of VR technology in psychedelic treatments with OVR Tech LLC. Press Release
  • Bionomics Ltd. (ASX: BNO) (OTC: BNOEF) recently announced plans to conduct a U.S. IPO of its ADSs on the NASDAQ. Press Release
  • PharmaTher Holdings Ltd. (CSE: PHRM) (OTC: PHRRF) recently announced that the FDA granted an Orphan Drug Designation for ketamine for the treatment of amyotrophic lateral sclerosis. Press Release
  • Wuhan General Group Inc. (OTC: WUHN) recently announced that a research team funded by the company successfully published a third paper on the Dovepress platform. Press Release
Read More

Featured Content

Medxtractor Doubles Down on B2B Licensing & mHealth

Medxtractor Corp. (CSE: MXT) (OTCQB: MXTTF) is known for its award-winning extraction equipment, but recently, the company refocused its efforts on its proprietary health-related databases, machine learning analysis, and plans to engage in B2B licensing and mHealth.

Industry Developments

  • What are the top psychedelic startups? via Business Insider
  • Psychedelics decriminalization advances in three more cities. via Marijuana Moment
  • Why psychedelics decriminalization only scratches the surface. via volteface